Irinotecan with trifluridine/tipiracil and bevacizumab for second-line metastatic colorectal cancer: a phase II multicenter study - PubMed
6 hours ago
- #Clinical Trial
- #Chemotherapy
- #Colorectal Cancer
- The study evaluated a combination of irinotecan, trifluridine/tipiracil (TAS-102), and bevacizumab as a second-line treatment for metastatic colorectal cancer (mCRC).
- The primary outcome was an objective response rate (ORR) of 18.3% and a disease control rate (DCR) of 83.3% in 60 enrolled patients.
- Median progression-free survival (PFS) was 6.6 months, and median overall survival (OS) was 17.3 months, with better outcomes in patients who had prior primary tumor resection.
- The most common treatment-related adverse events were nausea (100%), neutropenia (86.7%), and anemia (83.3%), with neutropenia being the most frequent grade 3/4 event.